OXB Oxford Biomedica plc
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide. Its LentiVector platform technology is a lentiviral vector based gene delivery system which is designed to overcome the safety and delivery problems associated with earlier generations of vector systems; InAAVate, a proprietary plug and play' dual-plasmid system for transient transfection, as well as a standard triple transfection system for AAV-based gene therapies. The company collaborates with pharmaceutical and biotechnology companies providing viral vector development and manufacturing services in lentivirus, adeno-associated virus, adenoviral vectors, and other viral vector types. The company was formerly known as Pinco 838 Limited and changed its name to Oxford Biomedica plc in October 1996. Oxford Biomedica plc was incorporated in 1996 and is headquartered in Oxford, the United Kingdom.…
Industry Peers
BiotechnologyKey Statistics
About Oxford Biomedica (LON: OXB)
›
Oxford Biomedica (LON: OXB) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 1,017 employees.
The shares were at 513.00 GBp on 19 November 2026, down 16.4% over 52 weeks. Its 52-week range is 420.00 GBp to 962.00 GBp: the price is 46.7% below the high and 22.1% above the low.
Its market capitalisation is 623.08M GBP.
Oxford Biomedica reports return on equity of -33.0%, an operating margin of -16.5% and revenue up 9.0% year over year.
Its debt exceeds its cash by 83.36M GBP, a debt-to-equity ratio of 1.62. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 8 analysts cover the stock, with an average rating of Buy; their mean price target of 689.63 GBp is 34.4% above the current price. The next earnings report is expected on 25 March 2027.